Niguldipine HCl has been reported to be a highly selective α 1-adrenoceptor antagonist and dihydropyridine calcium channel blocker. More specifically, Niguldipine HCl has been shown to irreversibly inhibit T-type calcium channel currents in certain types of central and peripheral neurons and in smooth muscle cells. This compound has also been noted to inhibit noradrenaline-stimulated inositol phosphate accumulation. Additional reports demonstrate that Niguldipine HCl can potently and specifically inhibit bTREK-1 (IC50 = 5.07μM). Niguldipine HCl is an inhibitor of Mdr-1.
1. Robinson, J.P., et al. 1990. Br. J. Pharmacol. 100: 3-4. PMID: 2164859
2. Höllt, V., et al. 1992. Biochem. Pharmacol. 43: 2601-2608. PMID: 1352973
3. Stengel, W., et al. 1998. Eur. J. Pharmacol. 342: 339-345. PMID: 9548406
4. Liu, H., et al. 2007. J. Pharmacol. Exp. Ther. 323: 39-48. PMID: 17622574
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.